
No Stock Yet
Editas, Beam Win Bullish Views as Cantor Launches Gene Editing Coverage
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15.The analyst says that following the recent pipeline reprioritization and p
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
UpgradesAccording to Alembic Global, the prior rating for Woodward Inc (NASDAQ:WWD) was changed from Neutral to Overweight. Woodward earned $0.49 in the first quarter, compared to $0.56 in the year-ag
Intellia Therapeutics Initiated at Overweight by Cantor Fitzgerald
Intellia Therapeutics Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Intellia Therapeutics With Overweight Rating, Announces Price Target of $67
Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Intellia Therapeutics with a Overweight rating and announces Price Target of $67.
Intellia Therapeutics Initiated With an Overweight at Cantor Fitzgerald
Raymond James & Associates Has $1.03 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Raymond James & Associates grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) by 34.6% in the third quarter, according to the company in its most recent 13F filing
Cathie Wood's ARK Investment Bought 195K Shares of Intellia Therapeutics Today
Intellia Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($1.31) Per Share (NASDAQ:NTLA)
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) – SVB Leerink issued their Q1 2023 earnings estimates for shares of Intellia Therapeutics in a research note issued on Monday, January 23rd.
Expert Ratings for Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings47100Last 30D001001M Ago02
Loading...
No Stock Yet